Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 Mar 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ibrutinib (Primary) ; Idelalisib (Primary) ; Corticosteroid; Thrombopoietin receptor agonists
Indications Autoimmune disorders; Autoimmune haemolytic anaemia; Chronic lymphocytic leukaemia; Idiopathic thrombocytopenic purpura; Pure red cell aplasia
Focus Therapeutic Use
Acronyms CABRI

04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
04 Dec 2018 Status changed from active, no longer recruiting to completed.
21 Mar 2018 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com